Subsequently, Ohara K. et al. [31] performed a prospective study with 36 patients with diabetic kidney disease (DKD) who were treated with SGLT-2 inhibitors to evaluate the changes in the fluid status measured by a BIA device (InBodyS10) at baseline and day 7. Here, SLC5A2 is linked to diabetic kidney disease.